Patricia Russo Magno, MD
Critical Care Medicine · Providence, RINPI 1184609422
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $699 of the $795 with a category attached, or 87.9%. 10 manufacturers reported payments, led by AstraZeneca at 34.5% of the total. Reporting peaked in 2023 at $452 and has fallen 92.5% since, to $34 in 2025.
Across 36 payments — averaging $22.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$274
- GSK$250
- Sanofi-aventis U.S. LLC$97
- Boehringer Ingelheim$45
- Philips North America LLC$34
- United Therapeutics Corporation$24
- plus $72 from 4 others
What the payments were for
- Food & beverage$69988%
- Education$9712%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $274 |
| GSK | 15 | $250 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| Boehringer Ingelheim | 2 | $45 |
| Philips North America LLC | 2 | $34 |
| United Therapeutics Corporation | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Sanofi | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Insmed, Inc. | 1 | $15 |
How this compares
Too few critical care medicine providers in Rhode Islandto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 888 | $688,144 |
| OfevNintedanib Esylate | 22 | $275,094 |
| TezspireTezepelumab-Ekko | 22 | $118,707 |
| Breo ElliptaFluticasone/Vilanterol | 218 | $106,463 |
| Spiriva RespimatTiotropium Bromide | 102 | $75,607 |
| Dupixent PenDupilumab | 18 | $65,157 |
| Pirfenidone | 19 | $46,739 |
| Dupixent SyringeDupilumab | 12 | $46,638 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 61 | $38,790 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 52 | $31,783 |
| Advair HfaFluticasone Propion/Salmeterol | 57 | $26,300 |
| SymbicortBudesonide/Formoterol Fumarate | 91 | $26,094 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $21,550 |
| Spiriva HandihalerTiotropium Bromide | 30 | $19,365 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 120 | $16,668 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $250 | $857,1891,265 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $45 | $372,251151 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $274 | $183,592174 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few critical care medicine providers in Rhode Islandon file to place this against a meaningful peer group, so we don't.
Other critical care medicine in Providence
- Mitchell LevyProvidence$17K
- Dimitra SkiadaProvidence$2K
- Archana PattuparaProvidence$811
- Gerardo CarinoProvidence$804
- Adeel AbbasiProvidence$388
- Rajiv PatelProvidence$322
- Samuel GilfeatherProvidence$276
- Christopher AllisonProvidence$140
- Jason GraffNarragansett$8K
- Taro MinamiPawtucket$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.